SOURCE: BASi (Bioanalytical Systems, Inc.)

February 20, 2006 14:37 ET

BASi and MicaGenix Announce Partnership

WEST LAFAYETTE, IN -- (MARKET WIRE) -- February 20, 2006 -- Bioanalytical Systems, Inc. (BASi) (NASDAQ: BASI) of West Lafayette, Indiana and MicaGenix, Inc. of Greenfield, Indiana, today announced a contract research partnership for complementary preclinical research services for pharmaceutical, medical device and biotechnology companies, as well as for medical schools.

Peter Kissinger, BASi Chairman and CEO, commented that, "For several years we have had common clients between several BASi laboratory sites and MicaGenix. There is very little overlap between our skill sets, and yet we have a number of opportunities to collaborate to the benefit of clients. MicaGenix leadership and technical staff benefit from many years of experience in association with Eli Lilly. This can now be put to work for the larger number of small discovery biology companies."

MicaGenix President Joe Parton noted, "The team at BASi has been in business longer than we have and it has been mutually beneficial to work with them as part of the Pharmaceutical Industry Contract Research Alliance (PICRA). We are delighted to formalize an even closer relationship whereby we each can market the services of the other and attract more business to Indiana. BASi has laboratory facilities in West Lafayette and Evansville, and an office in Indianapolis that we can share. MicaGenix is in Greenfield with close access to all three of those locations."

MicaGenix has a strong focus on mutagenicity work, histopathology services, and regulatory package preparation and review. BASi is a pharmaceutical development company providing contract research services generally downstream from MicaGenix in pharmacokinetics, pharmacodynamics, in vivo toxicology and clinical trials. The company focuses on developing innovative services and products that increase efficiency and reduce the cost of taking a new drug to market. Visit for more information about BASi, and for more about MicaGenix.

This release contains forward-looking statements that are subject to risks and uncertainties including, but not limited to, risks and uncertainties related to the development of products and services, changes in technology, industry standards and regulatory standards, and various market and operating risks detailed in the company's filings with the Securities and Exchange Commission.

Contact Information

    Edward M. Chait
    Email Contact